Browse by category

Flagship Pioneering, ProFound Therapeutics and Pfizer to identify novel first-in-class therapeutics for the treatment of obesity

Flagship Pioneering and ProFound Therapeutics have entered a collaboration to conduct foundational research to identify potential...

Pfizer’s twice-daily danuglipron formulation to be discontinued after high rates of GI complaints

Topline data from Pfizer’s Phase 2b clinical trial investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate,...

GLP-1-RA: Pfizer to continue danuglipron but discontinue lotiglipron

Pfizer will continue to progress its first full agonist oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate - danuglipron...

Gastric pouch resizing for recurrent weight gain promotes weight stabilisation in well-selected patients

4 days ago

COVID-19 pandemic: Bariatric surgery patients showed an increase in the percentage of weight regain

4 days ago

Semaglutide and liraglutide may reduce alcohol consumption in individuals with AUD

4 days ago

Weekly Digest